Testosterone and obesity

Obesity Reviews

Volumn 16, Issue 7, 2015, Pages 581-606

  Kelly, D M ^a   Jones, T H ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adipose; Androgen; Metabolism; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; LIPID; TESTOSTERONE; ANDROGEN RECEPTOR;

ADIPOGENESIS; ADIPOSE TISSUE; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; BODY COMPOSITION; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HUMAN; HYPOGONADISM; INFLAMMATION; LEAN BODY WEIGHT; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; MALE; META ANALYSIS (TOPIC); MITOCHONDRION; MUSCLE STEM CELL; NONHUMAN; OBESITY; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ADULT; BLOOD; COMPLICATION; DEFICIENCY; DRUG EFFECTS; HORMONE SUBSTITUTION; RISK FACTOR;

ADIPOSE TISSUE; ADULT; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; OBESITY; RECEPTORS, ANDROGEN; RISK FACTORS; TESTOSTERONE;

EID: 84931572998     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12282     Document Type: Article

References (334)

1. Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013; 217: R25-R45.
2. Santosa S, Jensen MD. Effects of male hypogonadism on regional adipose tissue fatty acid storage and lipogenic proteins. PLoS ONE 2012; 7: e31473.
3. Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 2009; 58: 803-812.
4. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R, Walker BR. Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes 2012; 61: 1072-1081.
5. O'Reilly MW, House PJ, Tomlinson JW. Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol 2014; 143: 277-284.
6. Xu XF, De Pergola G, Björntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991; 128: 379-382.
7. Ramirez ME, McMurry MP, Wiebke GA etal. Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 1997; 46: 179-185.
8. Rebuffé-Scrive M, Mårin P, Björntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991; 15: 791-795.
9. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80: 239-243.
10. Mårin P, Lönn L, Andersson B etal. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab 1996; 81: 1018-1022.
11. Maneschi E, Morelli A, Filippi S etal. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 2012; 215: 347-362.
12. Chen X, Li X, Huang HY, Li X, Lin JF. Effects of testosterone on insulin receptor substrate-1 and glucose transporter 4 expression in cells sensitive to insulin. Zhonghua Yi Xue Za Zhi 2006; 86: 1474-1477.
13. Singh AB, Hsia S, Alaupovic P etal. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87: 136-143.
14. Sato K, Iemitsu M, Aizawa K, Ajisaka R. Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 2008; 294: E961-E968.
15. Muthusamy T, Murugesan P, Balasubramanian K. Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat. Metabolism 2009; 58: 1581-1592.
16. Kelly DM, Akhtar S, Muraleedharan V etal. Testosterone differentially regulates liver X receptor expression and targets of lipid and glucose metabolism in liver, muscle and adipose tissue of the testicular feminised mouse. Endoc Abstr 2013; 32: P174.
17. Salehzadeh F, Rune A, Osler M, Al-Khalili L. Testosterone or 17{beta}-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. J Endocrinol 2011; 210: 219-229.
18. Allemand MC, Irving BA, Asmann YW etal. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes - a potential model for PCOS-related insulin resistance. PLoS ONE 2009; 4: e4274.
19. Bergamini E, Bombara G, Pellegrino C. The effect of testosterone on glycogen metabolism in rat levator ani muscle. Biochim Biophys Acta 1968; 177: 220-234.
20. Ramamani A, Aruldhas MM, Govindarajulu P. Differential response of rat skeletal muscle glycogen metabolism to testosterone and estradiol. Can J Physiol Pharmacol 1999; 77: 300-304.
21. Max SR, Knudsen JF. Effect of sex hormones on glucose-6-phosphate dehydrogenase in rat levator ani muscle. Mol Cell Endocrinol 1980; 17: 111-118.
22. Max SR. Androgen-estrogen synergy in rat levator ani muscle: glucose-6-phosphate dehydrogenase. Mol Cell Endocrinol 1984; 38: 103-107.
23. Powers ML, Florini JR. A direct effect of testosterone on muscle cells in tissue culture. Endocrinology 1975; 97: 1043-1047.
24. Joubert Y, Tobin C, Lebart MC. Testosterone-induced masculinization of the rat levator ani muscle during puberty. Dev Biol 1994; 162: 104-110.
25. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab 2003; 285: E197-E205.
26. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91: 3024-3033.
27. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-5088.
28. White JP, Gao S, Puppa MJ, Sato S, Welle SL, Carson JA. Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol 2013; 365: 174-186.
29. Ibebunjo C, Eash JK, Li C, Ma Q, Glass DJ. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement. Am J Physiol Endocrinol Metab 2011; 300: E327-E340.
30. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 2010; 151: 3706-3719.
31. Pitteloud N, Mootha VK, Dwyer AA etal. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636-1642.
32. Usui T, Kajita K, Kajita T etal. Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. FEBS Lett 2014; 588: 1935-1941.
33. Guo W, Wong S, Li M etal. Testosterone plus low-intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice. PLoS ONE 2012; 7: e51180.
34. Petersson SJ, Christensen LL, Kristensen JM, Kruse R, Andersen M, Højlund K. Effect of testosterone on markers of mitochondrial oxidative phosphorylation and lipid metabolism in muscle of aging men with subnormal bioavailable testosterone. Eur J Endocrinol 2014; 171: 77-88.
35. Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002; 13: 353-363.
36. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers 2002; 11(10 Pt 1): 1041-1047.
37. Jensen TK, Andersson AM, Jørgensen N etal. Body mass index in relation to semen quality and reproductive hormones among 1, 558 Danish men. Fertil Steril 2004; 82: 863-870.
38. Svartberg J, von Mühlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol 2004; 150: 65-71.
39. Svartberg J, von Mühlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromsø Study. Eur J Epidemiol 2004; 19: 657-663.
40. Corona G, Mannucci E, Ricca V etal. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32: 720-728.
41. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977; 45: 1211-1219.
42. Zumoff B, Strain GW, Miller LK etal. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990; 71: 929-931.
43. Pasquali R, Casimirri F, Cantobelli S etal. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991; 40: 101-104.
44. Laaksonen DE, Niskanen L, Punnonen K etal. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601-608.
45. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
46. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013; 10: 1612-1627.
47. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013; 27: 557-579.
48. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006; 176(4 Pt 1): 1524-1527.
49. Haffner S, Mykkanen L, Valdez R, Katz M. Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. J Clin Endocrinol Metab 1993; 77: 1610-1615.
50. Phillips G. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 1993; 42: 116-120.
51. Couillard C, Gagnon J, Bergeron J etal. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 2000; 85: 1026-1031.
52. Hofstra J, Loves S, van Wageningen B, Ruinemans-Koerts J, Jansen I, de Boer H. High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. Neth J Med 2008; 66: 103-109.
53. Dhindsa S, Miller MG, McWhirter CL etal. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-1192.
54. Corona G, Rastrelli G, Monami M etal. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013; 168: 829-843.
55. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes Rev 2005; 6: 67-85.
56. Maciejewski ML, Livingston EH, Smith VA etal. Survival among high-risk patients after bariatric surgery. JAMA 2011; 305: 2419-2426.
57. Himpens J, Cadière GB, Bazi M, Vouche M, Cadière B, Dapri G. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011; 146: 802-807.
58. Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 1981; 53: 828-832.
59. Pritchard J, Després JP, Gagnon J etal. Plasma adrenal, gonadal, and conjugated steroids following long-term exercise-induced negative energy balance in identical twins. Metabolism 1999; 48: 1120-1127.
60. Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes Res 2003; 11: 689-694.
61. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208-215.
62. Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010; 34: 1396-1403.
63. Globerman H, Shen-Orr Z, Karnieli E, Aloni Y, Charuzi I. Inhibin B in men with severe obesity and after weight reduction following gastroplasty. Endocr Res 2005; 31: 17-26.
64. Hammoud A, Gibson M, Hunt SC etal. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 2009; 94: 1329-1332.
65. Omana JJ, Tamler R, Strohmayer E, Herron D, Kini S. Sex hormone levels in men undergoing bariatric surgery. J Am Coll Surg 2009; 209(3 Suppl.): S22-S23.
66. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011; 96: 2341-2353.
67. Cohen P. The hypogonadalobesity-cycle. Med Hypothesis 1999; 52: 49-51.
68. Jones TH. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol 2007; 6: 847-857.
69. Finn PD, Cunningham MJ, Pau KY, Spies HG, Clifton DK, Steiner RA. The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. Endocrinology 1998; 139: 4652-4662.
70. Roseweir AK, Millar RP. The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 2009; 15: 203-212.
71. Isidori AM, Caprio M, Stroll F etal. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673-3680.
72. Krakoff J, Funahashi T, Stehouwer CD etal. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751.
73. Spranger J, Kroke A, Möhlig M etal. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
74. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004; 60: 500-507.
75. Page ST, Herbst KL, Amory JK etal. Testosterone administration suppresses adiponectin levels in men. J Androl 2005; 26: 85-92.
76. Kapoor D, Clarke S, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595-602.
77. Levine GN, D'Amico AV, Berger P etal. Androgendeprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-840.
78. Hamilton EJ, Gianatti E, Strauss BJ etal. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-383.
79. Smith JC, Bennett S, Evans LM etal. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-4267.
80. Smith MR, Finkelstein JS, McGovern FJ etal. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
81. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-745.
82. Smith MR, Lee H, McGovern F etal. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194.
83. van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol 2008; 68: 172-177.
84. Braga-Basaria M, Dobs AS, Muller DC etal. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-3983.
85. Misra KB, Endemann SW, Ayer M. Measures of obesity and metabolic syndrome in Indian Americans in northern California. Ethn Dis 2006; 16: 331-337.
86. Eknoyan G. Adolphe Quetelet (1796-1874) - the average man and indices of obesity. Nephrol Dial Transplant 2008; 23: 47-51.
87. Kawada T, Kuratomi Y, Kanai T etal. Anthropometric obesity indices and metabolic syndrome in Japanese working men. Work 2009; 34: 89-94.
88. Blundell JE, Dulloo AG, Salvador J, Frühbeck G, EASO SAB Working Group on BMI. Beyond BMI - phenotyping the obesities. Obes Facts 2014; 7: 322-328.
89. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
90. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161.
91. Ross R, Dagnone D, Jones PJ etal. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133: 92-103.
92. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2003; 79: 379-384.
93. Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev 2007; 29: 115-128.
94. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39: 897-901.
95. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239-250.
96. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999; 22(5 Suppl.): 110-116.
97. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
98. Pou KM, Massaro JM, Hoffmann U etal. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116: 1234-1241.
99. Pischon T, Boeing H, Hoffmann K etal. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120.
100. Misra A, Garg A, Abate N, Peshock RM, Stray-Gundersen J, Grundy SM. Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obes Res 1997; 5: 93-99.
101. Carey VJ, Walters EE, Colditz GA etal. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997; 145: 614-619.
102. Tankó LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003; 107: 1626-1631.
103. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 2000; 24: 485-491.
104. Garaulet M, Pérex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol 2000; 143: 657-666.
105. Nielsen TL, Hagen C, Wraae K etal. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 2007; 92: 2696-2705.
106. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522-4527.
107. Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi GM, Dandona P. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007; 30: 1860-1861.
108. Mauras N, Hayes V, Welch S etal. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83: 1886-1892.
109. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71: 318-322.
110. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010; 17: 240-246.
111. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012; 167: 531-541.
112. Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96: 1042-1052.
113. Lim S, Son KR, Song IC etal. Fat in liver/muscle correlates more strongly with insulin sensitivity in rats than abdominal fat. Obesity (Silver Spring) 2008; 17: 188-195.
114. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349-362.
115. Kley HK, Nieschlag E, Wiegelmann W, Solbach HG, Krüskemper HL. Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenh) 1975; 79: 275-285.
116. Völzke H, Aumann N, Krebs A etal. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010; 33: 45-53.
117. Kim S, Kwon H, Park JH etal. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 69.
118. Tian GX, Sun Y, Pang CJ etal. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 2012; 13: 381-387.
119. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014; 68: 314-329.
120. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with 'diabesity': results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014; 2014: 683515.
121. Stanworth RD, Kapoor D, Channer KS, Jones TH. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol 2008; 159: 739-746.
122. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007.
123. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 1988; 255(6 Pt 1): E769-E774.
124. Pourhassan M, Bosy-Westphal A, Schautz B, Braun W, Glüer CC, Müller MJ. Impact of body composition during weight change on resting energy expenditure and homeostasis model assessment index in overweight nonsmoking adults. Am J Clin Nutr 2014; 99: 779-791.
125. Lee CG, Boyko EJ, Nielson CM etal. Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J Am Geriatr Soc 2011; 59: 233-240.
126. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95: 1533-1543.
127. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 2010; 107: 123-136.
128. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr 2004; 80: 496-503.
129. Yuki A, Otsuka R, Kozakai R etal. Relationship between low free testosterone levels and loss of muscle mass. Sci Rep 2013; 3: 1818.
130. LeBlanc ES, Wang PY, Lee CG etal. Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metab 2011; 96: 3855-3863.
131. Tajar A, Huhtaniemi IT, O'Neill TW etal. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-1516.
132. Snyder PJ, Peachey H, Hannoush P etal. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-2653.
133. Bhasin S, Woodhouse L, Casaburi R etal. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90: 678-688.
134. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR etal. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
135. Sattler FR, Castaneda-Sceppa C, Binder EF etal. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009; 94: 1991-2001.
136. Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012; 34: 145-156.
137. Sattler F, Bhasin S, He J etal. Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci 2011; 66: 122-129.
138. Basaria S, Coviello AD, Travison TG etal. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
139. Bauman WA, Cirnigliaro CM, La Fountaine MF etal. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury. Horm Metab Res 2011; 43: 574-579.
140. Bhasin S, Calof OM, Storer TW etal. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2: 146-159.
141. Grinspoon S, Corcoran C, Askari H etal. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 18-26.
142. Grinspoon S, Corcoran C, Anderson E etal. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999; 28: 634-636.
143. Grinspoon S, Corcoran C, Parlman K etal. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000; 133: 348-355.
144. Bhasin S, Storer TW, Javanbakht M etal. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000; 283: 763-770.
145. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57: 141-147.
146. Fairfield WP, Treat M, Rosenthal DI etal. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. J Appl Physiol (1985) 2001; 90: 2166-2171.
147. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2: 692-699.
148. Knudsen J, Jensen MV, Hansen JK, Faergeman NJ, Neergaard TB, Gaigg B. Role of acylCoA binding protein in acylCoA transport, metabolism and cell signaling. Mol Cell Biochem 1999; 192: 95-103.
149. Gruen R, Hietanen E, Greenwood MR. Increased adipose tissue lipoprotein lipase activity during the development of the genetically obese rat (fa/fa). Metabolism 1978; 27(12 Suppl. 2): 1955-1966.
150. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060-1068.
151. Hansen FM, Fahmy N, Nielsen JH. The influence of sexual hormones on lipogenesis and lipolysis in rat fat cells. Acta Endocrinol (Copenh) 1980; 95: 566-570.
152. Xu X, De Pergola G, Björntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990; 126: 1229-1234.
153. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 2000; 24(Suppl. 2): S59-S63.
154. Pecquery R, Leneveu MC, Giudicelli Y. Influence of androgenic status on the alpha 2/beta-adrenergic control of lipolysis in white fat cells: predominant alpha 2-antilipolytic response in testosterone-treated-castrated hamsters. Endocrinology 1988; 122: 2590-2596.
155. Dicker A, Rydén M, Näslund E etal. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia 2004; 47: 420-428.
156. Karbowska J, Kochan Z. Fat-reducing effects of dehydroepiandrosterone involve upregulation of ATGL and HSL expression, and stimulation of lipolysis in adipose tissue. Steroids 2012; 77: 1359-1365.
157. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptor-deficient (ARKO) mice. Biochem Biophys Res Commun 2003; 300: 167-171.
158. Fan W, Yanase T, Nomura M etal. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005; 54: 1000-1008.
159. Yanase T, Fan W, Kyoya K etal. Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 2008; 109: 254-257.
160. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006; 7: 885-896.
161. Du J, Zhang L, Wang Z. Testosterone inhibits the activity of peroxisome proliferator-activated receptor gamma in a transcriptional transaction assay. Pharmazie 2009; 64: 692-693.
162. Graham TE, Yang Q, Blüher M etal. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.
163. Ost A, Danielsson A, Lidén M, Eriksson U, Nystrom FH, Strålfors P. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J 2007; 21: 3696-3704.
164. Schroeder ET, He J, Yarasheski KE etal. Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation. Eur J Appl Physiol 2012; 112: 1123-1131.
165. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998; 275(5 Pt 1): E864-E871.
166. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol 2008; 154: 522-528.
167. Kadi F, Eriksson A, Holmner S, Thornell LE. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Med Sci Sports Exerc 1999; 31: 1528-1534.
168. Kadi F. Adaptation of human skeletal muscle to training and anabolic steroids. Acta Physiol Scand Suppl 2000; 646: 1-52.
169. Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 2004; 166: 347-357.
170. Doumit ME, Cook DR, Merkel RA. Testosterone up-regulates androgen receptors and decreases differentiation of porcine myogenic satellite cells in vitro. Endocrinology 1996; 137: 1385-1394.
171. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 2004; 89: 5245-5255.
172. Fu R, Liu J, Fan J etal. Novel evidence that testosterone promotes cell proliferation and differentiation via G protein-coupled receptors in the rat L6 skeletal muscle myoblast cell line. J Cell Physiol 2011; 227: 98-107.
173. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 2010; 12: 537-577.
174. Mootha VK, Lindgren CM, Eriksson KF etal. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
175. Patti ME, Butte AJ, Crunkhorn S etal. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466-8471.
176. Hwang H, Bowen BP, Lefort N etal. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. Diabetes 2010; 59: 33-42.
177. Giebelstein J, Poschmann G, Højlund K etal. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia 2012; 55: 1114-1127.
178. Gastaldi G, Giacobino JP, Ruiz J. Metabolic syndrome, a mitochondrial disease? Rev Med Suisse 2008; 4: 1387-1388.
179. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-387.
180. Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK. Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 2005; 289: E266-E271.
181. Birzniece V, Meinhardt UJ, Handelsman DJ, Ho KK. Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): comparison of oral and transdermal testosterone administration in hypopituitary men. Clin Endocrinol (Oxf) 2009; 71: 715-721.
182. Ryu JW, Kim MS, Kim CH etal. DHEA administration increases brown fat uncoupling protein 1 levels in obese OLETF rats. Biochem Biophys Res Commun 2003; 303: 726-731.
183. Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 2012; 69: 1651-1667.
184. Scheller K, Sekeris CE. The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation. Exp Physiol 2003; 88: 129-140.
185. Psarra AM, Sekeris CE. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 2008; 60: 210-223.
186. Gavrilova-Jordan LP, Price TM. Actions of steroids in mitochondria. Semin Reprod Med 2007; 25: 154-164.
187. Fernando SM, Rao P, Niel L, Chatterjee D, Stagljar M, Monks DA. Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass. Endocrinology 2010; 151: 3125-3132.
188. Musa M, Fernando SM, Chatterjee D, Monks DA. Subcellular effects of myocyte-specific androgen receptor overexpression in mice. J Endocrinol 2011; 210: 93-104.
189. Pillar TM, Seitz HJ. Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Eur J Endocrinol 1997; 136: 231-239.
190. Scarpulla RC. Nuclear control of respiratory chain expression in mammalian cells. J Bioenerg Biomembr 1997; 29: 109-119.
191. Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009; 51: 303-313.
192. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539-545.
193. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807-811.
194. Simon D, Charles MA, Nahoul K etal. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-685.
195. Barud W, Palusiński R, Bełtowski J, Wójcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 2002; 164: 283-288.
196. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183-217.
197. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003; 104: 195-201.
198. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657-660.
199. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494-498.
200. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176: 520-525.
201. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166: 95-102.
202. Stanworth RD, Kapoor D, Channer KS, Jones TH. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clin Endocrinol (Oxf) 2011; 74: 624-630.
203. Haider A, Yassin A, Saad F, Shabsigh R. Effect of androgen deprivation on glycaemic control and on cardiovascular risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007; 10: 189-196.
204. Kiel DP, Baron JA, Plymate SR, Chute CG. Sex hormones and lipoproteins in men. Am J Med 1989; 87: 35-39.
205. Denti L, Pasolini G, Sanfelici L etal. Aging-related decline of gonadal function in healthy men: correlation with body composition and lipoproteins. J Am Geriatr Soc 2000; 48: 51-58.
206. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111: 261-269.
207. Isidori AM, Giannetta E, Greco EA etal. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-293.
208. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009; 207: 318-327.
209. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-733.
210. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007; 53: 353-357.
211. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844-3853.
212. Ozata M, Yildirimkaya M, Bulur M etal. Effects of gonadotropin and testosterone treatments on lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996; 81: 3372-3378.
213. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996; 77: 1244-1247.
214. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996; 122: 89-95.
215. Jones TH, Arver S, Behre HM etal. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-837.
216. Thompson PD, Cullinane EM, Sady SP etal. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165-1168.
217. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994; 79: 561-567.
218. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J etal. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121: 35-43.
219. Uyanik BS, Ari Z, Gümüs B, Yiğitoğlu MR, Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J 1997; 38: 73-82.
220. Boyanov M, Boneva Z, Christov V. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.
221. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313-3318.
222. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-612.
223. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
224. Gelaye B, Revilla L, Lopez T etal. Association between insulin resistance and c-reactive protein among Peruvian adults. Diabetol Metab Syndr 2010; 2: 30.
225. Olson NC, Callas PW, Hanley AJ etal. Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 2012; 97: 1032-1040.
226. Bose KS, Gupta SK, Vyas P. Adipocytokine levels in genetically high risk for type 2 diabetes in the Indian population: a cross-sectional study. Exp Diabetes Res 2012; 2012: 386524.
227. Patel C, Ghanim H, Ravishankar S etal. Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab 2007; 92: 4476-4479.
228. Schuster DP. Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation. Diabetes Metab Syndr Obes 2010; 3: 253-262.
229. Kelly DM, Sellers DJ, Woodroofe MN, Jones TH, Channer KS. Effect of testosterone on inflammatory markers in the development of early atherogenesis in the testicular-feminized mouse model. Endocr Res 2012; 38: 125-138.
230. Kelly DM, Nettleship JE, Akhtar S etal. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci 2014; 109: 95-103.
231. Vignozzi L, Filippi S, Comeglio P etal. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol Cell Endocrinol 2014; 384: 143-154.
232. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217: R47-R71.
233. Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. Mediators Inflamm 2013; 2013: 183041.
234. Yang YM, Lv XY, Huang WD, Xu ZR, Wu LJ. Study of androgen and atherosclerosis in old-age male. J Zhejiang Univ Sci B 2005; 6: 931-935.
235. Maggio M, Basaria S, Ble A etal. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006; 91: 345-347.
236. Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007; 39: 366-371.
237. Maggio M, Basaria S, Ceda GP etal. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 2005; 28(11 Suppl. Proceedings): 116-119.
238. Maggio M, Blackford A, Taub D etal. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 2006; 27: 725-728.
239. Malkin CJ, Pugh PJ, Morris PD etal. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-876.
240. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87: 1550-1554.
241. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2009; 118: 167-171.
242. Pugh PJ, Jones RD, Malkin CJ etal. Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res 2005; 31: 271-283.
243. Ng MK, Liu PY, Williams AJ etal. Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 2002; 22: 1136-1141.
244. Richard C, Couture P, Desroches S, Lamarche B. Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. Obesity (Silver Spring) 2013; 21: 51-57.
245. Xu A, Chan KW, Hoo RL etal. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-18080.
246. Pajvani UB, Hawkins M, Combs TP etal. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
247. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012; 8: 131-143.
248. Margo K, Winn R. Testosterone treatments: why, when, and how? Am Fam Physician 2006; 73: 1591-1598.
249. Bhasin S, Cunningham GR, Hayes FJ etal. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
250. Anderson RA, Martin CW, Kung AW etal. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3556-3562.
251. Wang C, Swerdloff RS, Iranmanesh A etal. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839-2853.
252. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-4343.
253. Wu FC, Tajar A, Beynon JM etal. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135.
254. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004; 89: 2837-2845.
255. Alexander GM, Swerdloff RS, Wang C etal. Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli. Horm Behav 1997; 31: 110-119.
256. O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav 2002; 75: 557-566.
257. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1, 438 men. J Sex Med 2013; 10: 579-588.
258. Caminiti G, Volterrani M, Iellamo F etal. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-927.
259. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57-64.
260. Wood RI. Oral testosterone self-administration in male hamsters: dose-response, voluntary exercise, and individual differences. Horm Behav 2002; 41: 247-258.
261. Morin LP, Cummings LA. Effect of surgical or photoperiodic castration, testosterone replacement or pinealectomy on male hamster running rhythmicity. Physiol Behav 1981; 26: 825-838.
262. Tamaki T, Uchiyama S, Uchiyama Y, Akatsuka A, Roy RR, Edgerton VR. Anabolic steroids increase exercise tolerance. Am J Physiol Endocrinol Metab 2001; 280: E973-E981.
263. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD, MacLean HE. Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab 2010; 301: E767-E778.
264. Swanson HH. Effects of castration at birth in hamsters of both sexes on luteinization of ovarian implants, oestrous cycles and sexual behaviour. J Reprod Fertil 1970; 21: 183-186.
265. Zucker I, Wade GN, Ziegler R. Sexual and hormonal influences on eating, taste preferences, and body weight of hamsters. Physiol Behav 1972; 8: 101-111.
266. Suzuki K, Jayasena CN, Bloom SR. Obesity and appetite control. Exp Diabetes Res 2012; 2012: 824305.
267. Mårin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1: 329-336.
268. Mårin P, Holmang S, Jonsson L etal. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991-997.
269. Agledahl I, Hansen JB, Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest 2008; 68: 641-648.
270. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008; 29: 102-105.
271. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008; 20: 378-387.
272. Woodhouse LJ, Gupta N, Bhasin M etal. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 2004; 89: 718-726.
273. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139-146.
274. Corona G, Monami M, Rastrelli G etal. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-283.
275. Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 2014; 16: 146-152.
276. Mårin P, Holmäng S, Gustafsson C etal. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245-251.
277. Aversa A, Bruzziches R, Francomano D etal. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495-3503.
278. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010; 33: 776-783.
279. Aversa A, Bruzziches R, Francomano D etal. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 2012; 15: 96-102.
280. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014; 83: 167-173.
281. Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 2014; 37: 401-411.
282. Haider A, Yassin A, Doros G, Traish AM, Saad F. Reductions of weight and waist size in 362 hypogonadal men with obesity grades I to III under long-term treatment with testosterone undecanoate (TU): observational data from two registry studies. Endocr Rev 2014; 35: SUN-0895.
283. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013; 21: 1975-1981.
284. Wang P, Menheere PP, Astrup A etal. Metabolic syndrome, circulating RBP4, testosterone, and SHBG predict weight regain at 6 months after weight loss in men. Obesity (Silver Spring) 2013; 21: 1997-2006.
285. Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. Aging Male 2014; 17: 1-11.
286. Hackett G, Cole N, Bhartia M etal. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014; 68: 203-215.
287. Hackett G, Cole N, Bhartia M etal. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014; 11: 840-856.
288. Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord 2011; 11: 18.
289. Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging 2012; 7: 321-330.
290. Garcia JA, Sanchez PE, Fraile C, Escovar P. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia 2011; 43: 293-296.
291. Zitzmann M, Saad F, Kliesch S. Long-term treatment with testosterone undecanoate injections leads to sustained weight loss and improvement of metabolic syndrome parameters in 381 hypogonadal men. J Sex Med 2014; 11(Suppl. 1): 7.
292. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-M272.
293. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 3167-3176.
294. Ferrando AA, Sheffield-Moore M, Yeckel CW etal. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601-E607.
295. Steidle C, Schwartz S, Jacoby K etal. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673-2681.
296. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58: 618-625.
297. Casaburi R, Bhasin S, Cosentino L etal. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 870-878.
298. Bhasin S, Parker RA, Sattler F etal. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007; 92: 1049-1057.
299. Srinivas-Shankar U, Roberts SA, Connolly MJ etal. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
300. Behre HM, Tammela TL, Arver S etal. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012; 15: 198-207.
301. Finkelstein JS, Lee H, Burnett-Bowie SA etal. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369: 1011-1022.
302. Bouloux PM, Legros JJ, Elbers JM etal. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male 2013; 16: 38-47.
303. Juang PS, Peng S, Allehmazedeh K, Shah A, Coviello AD, Herbst KL. Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. J Sex Med 2014; 11: 563-573.
304. Rodriguez-Tolrà J, Torremadé Barreda J, del Rio L, di Gregorio S, Franco Miranda E. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male 2013; 16: 184-190.
305. Borst SE, Yarrow JF, Conover CF etal. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab 2014; 306: E433-E442.
306. Traish AM. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014; 21: 313-322.
307. Wang C, Eyre DR, Clark R etal. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3654-3662.
308. Bhasin S, Storer TW, Berman N etal. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-413.
309. Snyder PJ, Peachey H, Berlin JA etal. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677.
310. Lovejoy JC, Bray GA, Greeson CS etal. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995; 19: 614-624.
311. Münzer T, Harman SM, Hees P etal. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001; 86: 3604-3610.
312. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469-3475.
313. Bhasin S, Woodhouse L, Casaburi R etal. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172-E1181.
314. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358-4365.
315. Schroeder ET, Singh A, Bhasin S etal. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Am J Physiol Endocrinol Metab 2003; 284: E120-E128.
316. Schroeder ET, Zheng L, Ong MD etal. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89: 4863-4872.
317. Nair KS, Rizza RA, O'Brien P etal. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355: 1647-1659.
318. Allan CA, Strauss BJ, McLachlan RI. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007; 19: 448-457.
319. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011; 165: 675-685.
320. Bhasin S, Travison TG, Storer TW etal. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012; 307: 931-939.
321. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014; 2014: 527470.
322. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013; 3: 73-83.
323. Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 2014; 15: 1903-1926.
324. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014; 8: e339-e349.
325. Moisey R, Swinburne J, Orme S. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000mg IM - Nebido). Clin Endocrinol (Oxf) 2008; 69: 642-647.
326. Winter A, Marte A, Kelly M, Funaro M, Schlegel P, Paduch D. Predictors of poor response to transdermal testosterone therapy in men with metabolic syndrome. J Urol 2014; 191(Suppl. 4): e528.
327. Heald AH, Anderson SG, Ivison F etal. Low sex hormone binding globulin is a potential marker for the metabolic syndrome in different ethnic groups. Exp Clin Endocrinol Diabetes 2005; 113: 522-528.
328. Vigen R, O'Donnell CI, Baron A etal. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829-1836.
329. FDA (2014). Briefing information for the September 17, 2014 joint meeting. Bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee. [WWW document]. URL http://www.fda.gov/downloads/AdvisoryCommittee/.../UCM412536.pdf (accessed November 19, 2014).
330. FDA (2014). Advisory committee industry briefing document. Testosterone therapy. Bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee. [WWW document]. URL http://www.fda.gov/downloads/AdvisoryCommittee/.../UCM412537.pdf (accessed November 19, 2014).
331. European Medicines Agency (2014). No consistent evidence of an increased risk of heart problems with testosterone medicines. [WWW document]. URL http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f (accessed November 19, 2014).
332. Finkle WD, Greenland S, Ridgeway GK etal. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PlosOne 2014; 9: 1-7.
333. Corona G, Maseroli E, Rastrelli G etal. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13: 1327-1351.
334. Baillargeon J, Urban RJ, Kuo YF etal. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacol 2014; 48: 1138-1144.